GRI Bio (NASDAQ:GRI) Now Covered by Ascendiant Capital Markets

by · The Cerbat Gem

Stock analysts at Ascendiant Capital Markets started coverage on shares of GRI Bio (NASDAQ:GRI – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $12.00 price target on the stock.

GRI Bio Trading Up 8.9 %

GRI stock opened at 0.43 on Tuesday. GRI Bio has a fifty-two week low of 0.30 and a fifty-two week high of 154.70. The business’s 50 day moving average price is 0.49 and its two-hundred day moving average price is 3.03.

GRI Bio (NASDAQ:GRI – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported -4.92 earnings per share for the quarter.

Institutional Trading of GRI Bio

A hedge fund recently bought a new stake in GRI Bio stock. Armistice Capital LLC purchased a new position in GRI Bio, Inc. (NASDAQ:GRI – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 50,207 shares of the company’s stock, valued at approximately $96,000. Armistice Capital LLC owned approximately 9.23% of GRI Bio as of its most recent SEC filing. 33.95% of the stock is currently owned by hedge funds and other institutional investors.

About GRI Bio

(Get Free Report)

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.

See Also